https://www.nasdaq.com/press-release/affimed-to-present-at-the-40th-annual-j.p.-morgan-healthcare-conference-2022-01-05
https://www.nasdaq.com/press-release/affimed-shares-preclinical-data-on-innate-cell-engagers-afm28-and-afm13-at-the-63rd
https://www.nasdaq.com/press-release/affimed-to-host-virtual-investor-call-today-to-discuss-treatment-of-cd30-positive
https://www.nasdaq.com/press-release/affimed-initiates-patient-recruitment-for-a-phase-1-2a-trial-of-innate-cell-engager
https://www.nasdaq.com/press-release/affimed-announces-100-objective-response-rate-at-highest-dose-in-phase-1-2-study-of
https://www.nasdaq.com/press-release/affimed-shares-preclinical-data-on-mechanism-of-action-of-two-innate-cell-engagers-at
https://www.nasdaq.com/press-release/affimed-reports-third-quarter-2021-financial-results-and-highlights-operational
https://www.nasdaq.com/press-release/affimed-to-present-at-upcoming-investor-conferences-2021-11-09
https://www.nasdaq.com/press-release/affimed-and-nkgen-biotech-announce-initiation-of-patient-recruitment-in-a-first-in
https://www.nasdaq.com/press-release/affimed-announces-new-innate-cell-engager-afm28-targeting-cd123-to-treat-acute
https://www.nasdaq.com/press-release/affimed-announces-poster-presentations-at-the-63rd-american-society-of-hematology
https://www.nasdaq.com/press-release/affimed-to-report-third-quarter-2021-financial-results-corporate-update-on-november
https://www.nasdaq.com/press-release/affimed-announces-acceptance-of-three-abstracts-with-preclinical-data-on-its-innate
https://www.nasdaq.com/press-release/affimed-reports-second-quarter-2021-financial-results-and-highlights-operational
https://www.nasdaq.com/press-release/affimed-to-present-at-upcoming-investor-conferences-2021-08-26
https://www.nasdaq.com/press-release/affimed-to-report-second-quarter-2021-financial-results-corporate-update-on-september
https://www.nasdaq.com/press-release/affimed-announces-publication-of-comprehensive-preclinical-data-demonstrating-the
https://www.nasdaq.com/press-release/affimed-reports-first-quarter-2021-financial-results-and-highlights-operational
https://www.nasdaq.com/press-release/affimed-to-report-first-quarter-2021-financial-results-corporate-update-july-1-2021
https://www.nasdaq.com/press-release/affimed-announces-appointment-of-uta-kemmerich-keil-to-its-supervisory-board-2021-06
https://www.nasdaq.com/press-release/affimed-to-present-at-the-jefferies-virtual-healthcare-conference-2021-2021-05-26
https://www.nasdaq.com/press-release/affimed-announces-virtual-annual-general-meeting-of-shareholders-2021-05-20
https://www.nasdaq.com/press-release/affimed-announces-publication-of-preclinical-data-in-clinical-cancer-research
https://www.nasdaq.com/press-release/affimed-reports-2020-financial-results-and-highlights-recent-operational-progress
https://www.nasdaq.com/press-release/affimed-highlights-the-potential-of-its-innate-cell-engager-afm24-as-egfr-targeting
https://www.nasdaq.com/press-release/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study
https://www.nasdaq.com/press-release/affimed-to-report-full-year-2020-financial-results-corporate-update-on-april-15-2021
https://www.nasdaq.com/press-release/affimed-and-nkmax-america-announce-fda-clearance-of-ind-application-to-study-the
https://www.nasdaq.com/press-release/affimed-announces-presentations-at-the-aacr-annual-meeting-2021-2021-03-10
https://www.nasdaq.com/press-release/affimed-announces-continuation-of-redirect-a-registration-directed-study-of-afm13-in
https://www.nasdaq.com/press-release/affimed-announces-collaboration-with-roche-to-study-afm24-in-combination-with-pd-l1
https://www.nasdaq.com/press-release/affimed-announces-closing-of-public-offering-of-common-shares-and-full-exercise-of
https://www.nasdaq.com/press-release/affimed-announces-pricing-of-%24100000000-public-offering-of-common-shares-2021-01-13
https://www.nasdaq.com/press-release/affimed-announces-proposed-public-offering-of-common-shares-2021-01-12
https://www.nasdaq.com/press-release/affimed-to-present-at-the-39th-annual-j.p.-morgan-healthcare-conference-2021-01-11
https://www.nasdaq.com/press-release/affimed-announces-eu25-million-debt-financing-agreement-with-silicon-valley-bank-2021
https://www.nasdaq.com/press-release/affimed-announces-pipeline-and-business-update-2021-01-07
https://www.nasdaq.com/press-release/affimed-announces-updated-afm13-clinical-data-presentation-at-the-american-society-of
https://www.nasdaq.com/press-release/affimed-announces-publication-of-final-study-results-of-its-innate-cell-engager
https://www.nasdaq.com/press-release/affimed-reports-third-quarter-2020-financial-results-and-highlights-recent
https://www.nasdaq.com/press-release/affimed-and-roivant-sciences-announce-licensing-and-strategic-collaboration-agreement
https://www.nasdaq.com/press-release/new-preclinical-data-being-presented-at-sitc-underscore-promising-combinations-of
https://www.nasdaq.com/press-release/artiva-biotherapeutics-and-affimed-announce-platform-to-platform-rd-collaboration-for
https://www.nasdaq.com/press-release/affimed-announces-presentations-on-its-afm13-innate-cell-engager-at-the-62nd-american
https://www.nasdaq.com/press-release/affimed-to-present-at-upcoming-investor-conferences-2020-11-04
https://www.nasdaq.com/press-release/affimed-to-report-3rd-quarter-2020-financial-results-corporate-update-november-10
https://www.nasdaq.com/press-release/affimed-and-nkmax-america-to-study-the-combination-of-afm24-an-egfr-targeted-innate
https://www.nasdaq.com/press-release/affimed-announces-presentation-of-preclinical-data-on-afm13-targeted-nk-cells-at-the
https://www.nasdaq.com/press-release/abcheck-s.r.o.-receives-grant-to-further-develop-a-discovery-technology-for
https://www.nasdaq.com/press-release/affimed-announces-dosing-of-first-patient-in-phase-1-clinical-trial-of-cord-blood
https://www.nasdaq.com/press-release/affimed-to-present-at-jefferies-virtual-cell-therapy-summit-2020-09-29
https://www.nasdaq.com/press-release/affimed-to-present-at-upcoming-investor-conferences-2020-09-02
